Spanish regulator slaps Angulema with noncompliance; orders recall of vaccines

Angulema has been ordered to recall more than 400 lots of its vaccines due to noncompliant manufacturing processes.

Madrid-based vaccine maker Angulema has been slapped by the Spanish Agency of Medicines and Medical Devices with noncompliance in its manufacturing processes and was ordered to recall more than 400 lots of its vaccines.

The action by Spain’s regulatory agency was posted on the European Medicines Agency (EMA)  EudraGMDP site that was established to alert other European Commission countries that might also receive products from plants that have been cited.

During a November inspection of the Angulema facility, Spanish inspectors found critical and major deficiencies in the company’s quality system and manufacturing processes for products that included subcutaneous, sublingual and nasal formulations of bacterial vaccines, bacterial autovaccines, and allergenic vaccines.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

The agency said the company did not have an effective pharmaceutical quality system and that Angulema released "batches of bacterial vaccines and bacterial auto-vaccines … without performing the sterility test according to [the European Pharmacopoeia] Eu. Ph.”

Additionally, inspectors found that a series of required process validation and media fill process simulations for aseptic processes were not conducted, and that the company didn’t perform validation activities for ensuring its bacterial vaccines and bacterial autovaccines were sterile and inactive.

Earlier this year, regulators in Spain found issues with the Alcor plant in Guadalajara, Spain, and a Barcelona facility owned by Farma Mediterrania. In the Farma Mediterrania case, inspectors found the facility lacked an effective quality-assurance system, released batches without completing manufacturing protocols and used nonqualified equipment and procedures, among other violations.

Suggested Articles

Pfizer says two lots of migraine med Relpax failed to meet microbial standards and may be contaminated with genera pseudomonas and burkholderia.

Emcure has had its share of run-ins with the FDA in the past over the sterility of its plants. Now, it can notch one more black mark on its belt.

The FDA has slapped a warning letter on an Indian solvent recycler that may have contributed to the contamination of blood pressure meds.